European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 143, Issue 2 , Pages 88-92 , April 2009

Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma

  • K. Galaal

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • Corresponding Author InformationCorresponding author at: Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Sheriff Hill, Gateshead NE9 6SX, UK. Tel.: +44 191 4452597; fax: +44 191 4456192.
    • ,
  • F.M. Kew

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • K.F. Tam

      Affiliations

    • Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong
    • ,
  • A. Lopes

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • M. Meirovitz

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • R. Naik

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • K.A. Godfrey

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • M.H. Hatem

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • R.J. Edmondson

      Affiliations

    • Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK

Received 20 June 2007 ,Revised 8 September 2008 ,Accepted 29 December 2008.

References 

  1. Vaccarello L, Curtin J. Presentation and management of carcinosarcoma of the uterus. Oncology (Williston Park). 1992;6(5):45–49
  2. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88(12):2782–2786
  3. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006;100(3):561–564
  4. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer. 2002;12(4):348–353
  5. Omura G, Blessing J, Major F, Lifshitz S, Ehrlich C, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–1245
  6. Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol. 1995;56(3):370–375
  7. Barwick KW, LiVolsi VA. Malignant mixed mullerian tumor of the uterus. Am J Surg Pathol. 1979;3:125–135
  8. Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer. 1998;82(3):512–519
  9. Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol. 1997;67(3):316–321
  10. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Cosio S, et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol. 2002;23(4):295–299
  11. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58(3):786–796
  12. Nielsen SN, Podratz KC, Scheithauer BW, O’Brien PC. Clinicopathologic analysis of uterine malignant mixed müllerian tumors. Gynecol Oncol. 1989;34(3):372–378
  13. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65(3):493–498
  14. Sartori E, Bazzurini L, Gadducci A, Landoni F, Lissoni A, Maggino T, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997;67(1):70–75
  15. Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005;97(1):166–170
  16. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91(8):1437–1443
  17. Knocke TH, Weitmann HD, Kucera H, Kolbl H, Pokrajac B, Potter R. Results of primary and adjuvent radiotherapy in the treatment of mixed mullerian tumors of the corpus uteri. Gynecol Oncol. 1999;73:389–395
  18. Perez CA, Askin F, Baglan RJ, Kao MS, Kraus FT, Perez BM, et al. Effects of irradiation on mixed mullerian tumors of the uterus. Cancer. 1979;43(4):1274–1284
  19. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003;90(3):529–536
  20. Fowler JM, Blessing JA, Burger RA, Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2002;85(2):311–314
  21. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998;68(1):8–13
  22. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988;71:845–850
  23. Spanos W, Peters L, Oswald M. Patterns of recurrence in malignant mixed mesodermal mullerian tumors of the uterus. Cancer. 1986;57:155–159
  24. Kohorn EI, Schwartz PE, Chambers JT, Peschel RE, Kapp DS, Merino M. Adjuvent therapy in mixed mullerian tumors of the uterus. Gynecol Oncol. 1986;23(2):212–221
  25. Macasaet MA, Waxman M, Fruchter RG, Boyce J, Hong P, Nicastri AD, et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol. 1985;20:32–42
  26. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol. 1997;65(1):158–163
  27. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9(1):1–19
  28. Peters WA, Kumar NB, Fleming WP, Morley GW. Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol. 1984;63(4):550–556
  29. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96(3):630–634
  30. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526–53110.1200/JCO.2006.06.4907
  31. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stages I–IV carcinosarcoma (CS) of the uterus [see comment]. Gynecol Oncol. 2007;107(November (2)):177–185

PII: S0301-2115(09)00003-7

doi: 10.1016/j.ejogrb.2008.12.014

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 143, Issue 2 , Pages 88-92 , April 2009

Article Tools

* Image Usage & Resolution